Nishan de Silva Biography and Net Worth

Director of Selecta Biosciences

Presently, Nishan M. de Silva is Chief Executive Officer & Director at AFYX Therapeutics AS.

He is also on the board of Selecta Biosciences, Inc., Transposagen Biopharmaceuticals, Inc., Alita Pharmaceuticals, Inc. and CONNECT.

In the past he was President, Chief Operating Officer & Director at Poseida Therapeutics, Inc., Chief Financial Officer & Vice President-Strategy at Ligand Pharmaceuticals, Inc., Principal at McKinsey & Co., Inc., Principal at Sprout Group and Principal at Warburg Pincus LLC.

He received a doctorate from Perelman School of Medicine, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Harvard College.

How do I contact Nishan M. de Silva?: The corporate mailing address for Mr. de Silva and other Selecta Biosciences executives is 65 Grove Street, Watertown MA, 02472. Selecta Biosciences can also be reached via phone at (617) 923-1400 and via email at [email protected]. Learn More on Nishan M. de Silva's contact information.
Has Nishan M. de Silva been buying or selling shares of Selecta Biosciences?: Nishan M. de Silva has not been actively trading shares of Selecta Biosciences in the last ninety days. Most recently, on Thursday, December 2nd, Nishan M. Desilva bought 7,000 shares of Selecta Biosciences stock. The stock was acquired at an average cost of $2.96 per share, with a total value of $20,720.00. Learn More on Nishan M. de Silva's trading history.
Who are Selecta Biosciences' active insiders?: Selecta Biosciences' insider roster includes Timothy Barabe (Director), Carsten Brunn (CEO), Nishan de Silva (Director), Timothy Springer (Director), Kevin Tan (CFO), and Peter Traber (Insider). Learn More on Selecta Biosciences' active insiders.
Are insiders buying or selling shares of Selecta Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 3,637 shares worth more than $3,855.22. The most recent insider tranaction occured on September, 25th when CEO Carsten Brunn sold 2,932 shares worth more than $3,107.92. Insiders at Selecta Biosciences own 31.2% of the company. Learn More about insider trades at Selecta Biosciences.
Information on this page was last updated on 9/25/2023.

Nishan M. de Silva Insider Trading History at Selecta Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/2/2021	Buy	7,000	$2.96	$20,720.00

Nishan M. de Silva Buying and Selling Activity at Selecta Biosciences

Selecta Biosciences Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $1.06

$0.88

$1.26

2 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.